Star Combo Pharma (ASX:S66) Debt-to-EBITDA : 3.38 (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Star Combo Pharma Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Star Combo Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was A$0.15 Mil. Star Combo Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was A$3.79 Mil. Star Combo Pharma's annualized EBITDA for the quarter that ended in Dec. 2024 was A$1.17 Mil. Star Combo Pharma's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was 3.37.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Star Combo Pharma's Debt-to-EBITDA or its related term are showing as below:

ASX:S66' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -32.45 Med: -0.27 Max: 15.99
Current: 1.32

During the past 7 years, the highest Debt-to-EBITDA Ratio of Star Combo Pharma was 15.99. The lowest was -32.45. And the median was -0.27.

ASX:S66's Debt-to-EBITDA is ranked better than
60.41% of 1503 companies
in the Consumer Packaged Goods industry
Industry Median: 2.02 vs ASX:S66: 1.32

Star Combo Pharma Debt-to-EBITDA Historical Data

The historical data trend for Star Combo Pharma's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Star Combo Pharma Debt-to-EBITDA Chart

Star Combo Pharma Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Debt-to-EBITDA

Get a 7-Day Free Trial

15.99

-0.52

-32.45

-1.66

1.45

Star Combo Pharma Semi-Annual Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Debt-to-EBITDA	Get a 7-Day Free Trial									-0.48	1.28	5.20	0.84	3.38

Competitive Comparison of Star Combo Pharma's Debt-to-EBITDA

For the Household & Personal Products subindustry, Star Combo Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Star Combo Pharma's Debt-to-EBITDA Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Star Combo Pharma's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Star Combo Pharma's Debt-to-EBITDA falls into.

Save Embed

;

Save Embed

;

Star Combo Pharma Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Star Combo Pharma's Debt-to-EBITDA for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.157	+	3.871)	/	2.787
	=	1.45

Star Combo Pharma's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.149	+	3.786)	/	1.166
	=	3.37

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2024) EBITDA data.

Star Combo Pharma (ASX:S66) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Star Combo Pharma Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Star Combo Pharma's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Star Combo Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Star Combo Pharma Ltd (ASX:S66) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

171 - 177 Woodpark Road, Smithfield, Sydney, NSW, AUS, 2164

Website

https://www.starcombo.com.au

Star Combo Pharma Ltd is engaged in the manufacturing and distribution of food products and nutritional supplements. The company offers products such as face masks, moisturizing creams, serums, concentrates, and oils. Star Combo Pharma markets its products. It operates in two segments. Star Combo segment engages in the development, manufacturing, marketing and sales of natural health supplements and skincare products. The Austoyou retail business segment has made up of the Australia-China e-commerce platform that offers product lines directly to Chinese health product consumers; and Koala Mall's two retail stores in Sydney. Geographically, it operates in China and Australia.

Star Combo Pharma Headlines

No Headlines